An antibody or antigen-binding fragment thereof that binds human CGRP receptor comprising a CDRH1, a CDRH2, a CDRH3, a CDRL1, a CDRL2 and a CDRL3, wherein: (a) CDRL1, CDRL2, and CDRL3 have the sequence of SEQ ID NOs: 42, 43 and 44, respectively, and CDRH1, CDRH2, and CDRH3 have the sequence of SEQ ID NOs: 73, 74 and 75, respectively; (b) CDRL1, CDRL2, and CDRL3 have the sequence of SEQ ID NOs: 45, 46 and 47, respectively, and CDRH1, CDRH2, and CDRH3 have the sequence of SEQ ID NOs: 76, 77 and 78, respectively; (c) CDRL1, CDRL2, and CDRL3 have the sequence of SEQ ID NOs: 48, 49 and 50, respectively, and CDRH1, CDRH2, and CDRH3 have the sequence of SEQ ID NOs: 79, 80 and 81, respectively; (d) CDRL1, CDRL2, and CDRL3 have the sequence of SEQ ID NOs: 51, 52 and 53, respectively, and CDRH1, CDRH2, and CDRH3 have the sequence of SEQ ID NOs: 82, 83 and 84, respectively; (e) CDRL1, CDRL2, and CDRL3 have the sequence of SEQ ID NOs: 54, 55 and 56, respectively, and CDRH1, CDRH2, and CDRH3 have the sequence of SEQ ID NOs: 85, 86 and 87, respectively; (f) CDRL1, CDRL2, and CDRL3 have the sequence of SEQ ID NOs: 57, 58 and 59, respectively, and CDRH1, CDRH2, and CDRH3 have the sequence of SEQ ID NOs: 88, 89 and 90, respectively; (g) CDRL1, CDRL2, and CDRL3 have the sequence of SEQ ID NOs: 60, 55 and 56, respectively, and CDRH1, CDRH2, and CDRH3 have the sequence of SEQ ID NOs: 85, 86 and 87, respectively; (h) CDRL1, CDRL2, and CDRL3 have the sequence of SEQ ID NOs: 45, 61 and 47, respectively, and CDRH1, CDRH2, and CDRH3 have the sequence of SEQ ID NOs: 76, 91 and 78, respectively; (i) CDRL1, CDRL2, and CDRL3 have the sequence of SEQ ID NOs: 62, 63 and 64, respectively, and CDRH1, CDRH2, and CDRH3 have the sequence of SEQ ID NOs: 92, 93 and 94, respectively; (j) CDRL1, CDRL2, and CDRL3 have the sequence of SEQ ID NOs: 45, 61 and 47, respectively, and CDRH1, CDRH2, and CDRH3 have the sequence of SEQ ID NOs: 76, 95 and 78, respectively; (k) CDRL1, CDRL2, and CDRL3 have the sequence of SEQ ID NOs: 65, 55 and 56, respectively, and CDRH1, CDRH2, and CDRH3 have the sequence of SEQ ID NOs: 85, 86 and 87, respectively; (l) CDRL1, CDRL2, and CDRL3 have the sequence of SEQ ID NOs: 42, 43 and 44, respectively, and CDRH1, CDRH2, and CDRH3 have the sequence of SEQ ID NOs: 73, 74 and 96, respectively; (m) CDRL1, CDRL2, and CDRL3 have the sequence of SEQ ID NOs: 66, 67 and 68, respectively, and CDRH1, CDRH2, and CDRH3 have the sequence of SEQ ID NOs: 97, 98 and 99, respectively; (n) CDRL1, CDRL2, and CDRL3 have the sequence of SEQ ID NOs: 69, 70 and 71, respectively, and CDRH1, CDRH2, and CDRH3 have the sequence of SEQ ID NOs: 100, 101 and 102, respectively; or (o) CDRL1, CDRL2, and CDRL3 have the sequence of SEQ ID NOs: 69, 70 and 72, respectively, and CDRH1, CDRH2, and CDRH3 have the sequence of SEQ ID NOs: 100, 101 and 102, respectively. (a) CDRL1, CDRL2, and CDRL3 have the sequence of SEQ ID NOs: 42, 43 and 44, respectively, and CDRH1, CDRH2, and CDRH3 have the sequence of SEQ ID NOs: 73, 74 and 75, respectively; (b) CDRL1, CDRL2, and CDRL3 have the sequence of SEQ ID NOs: 45, 46 and 47, respectively, and CDRH1, CDRH2, and CDRH3 have the sequence of SEQ ID NOs: 76, 77 and 78, respectively; (c) CDRL1, CDRL2, and CDRL3 have the sequence of SEQ ID NOs: 48, 49 and 50, respectively, and CDRH1, CDRH2, and CDRH3 have the sequence of SEQ ID NOs: 79, 80 and 81, respectively; (d) CDRL1, CDRL2, and CDRL3 have the sequence of SEQ ID NOs: 51, 52 and 53, respectively, and CDRH1, CDRH2, and CDRH3 have the sequence of SEQ ID NOs: 82, 83 and 84, respectively; (e) CDRL1, CDRL2, and CDRL3 have the sequence of SEQ ID NOs: 54, 55 and 56, respectively, and CDRH1, CDRH2, and CDRH3 have the sequence of SEQ ID NOs: 85, 86 and 87, respectively; (f) CDRL1, CDRL2, and CDRL3 have the sequence of SEQ ID NOs: 57, 58 and 59, respectively, and CDRH1, CDRH2, and CDRH3 have the sequence of SEQ ID NOs: 88, 89 and 90, respectively; (g) CDRL1, CDRL2, and CDRL3 have the sequence of SEQ ID NOs: 60, 55 and 56, respectively, and CDRH1, CDRH2, and CDRH3 have the sequence of SEQ ID NOs: 85, 86 and 87, respectively; (h) CDRL1, CDRL2, and CDRL3 have the sequence of SEQ ID NOs: 45, 61 and 47, respectively, and CDRH1, CDRH2, and CDRH3 have the sequence of SEQ ID NOs: 76, 91 and 78, respectively; (i) CDRL1, CDRL2, and CDRL3 have the sequence of SEQ ID NOs: 62, 63 and 64, respectively, and CDRH1, CDRH2, and CDRH3 have the sequence of SEQ ID NOs: 92, 93 and 94, respectively; (j) CDRL1, CDRL2, and CDRL3 have the sequence of SEQ ID NOs: 45, 61 and 47, respectively, and CDRH1, CDRH2, and CDRH3 have the sequence of SEQ ID NOs: 76, 95 and 78, respectively; (k) CDRL1, CDRL2, and CDRL3 have the sequence of SEQ ID NOs: 65, 55 and 56, respectively, and CDRH1, CDRH2, and CDRH3 have the sequence of SEQ ID NOs: 85, 86 and 87, respectively; (l) CDRL1, CDRL2, and CDRL3 have the sequence of SEQ ID NOs: 42, 43 and 44, respectively, and CDRH1, CDRH2, and CDRH3 have the sequence of SEQ ID NOs: 73, 74 and 96, respectively; (m) CDRL1, CDRL2, and CDRL3 have the sequence of SEQ ID NOs: 66, 67 and 68, respectively, and CDRH1, CDRH2, and CDRH3 have the sequence of SEQ ID NOs: 97, 98 and 99, respectively; (n) CDRL1, CDRL2, and CDRL3 have the sequence of SEQ ID NOs: 69, 70 and 71, respectively, and CDRH1, CDRH2, and CDRH3 have the sequence of SEQ ID NOs: 100, 101 and 102, respectively; or (o) CDRL1, CDRL2, and CDRL3 have the sequence of SEQ ID NOs: 69, 70 and 72, respectively, and CDRH1, CDRH2, and CDRH3 have the sequence of SEQ ID NOs: 100, 101 and 102, respectively.